However, knockdown of K19 in MDA-MB-231 and MCF7 cells increased resistance to doxorubicin (Figure 2C) [70], and overexpression of K19 in BT549 breast cancer cell line resulted in decreased sensitivity towards cisplatin and doxorubicin (Figure 2C) [90]. Here, KRT19 is linked to breast carcinoma.